Provided by Tiger Fintech (Singapore) Pte. Ltd.

Revolution Medicines, Inc.

40.16
-0.5100-1.25%
Volume:297.67K
Turnover:11.84M
Market Cap:7.47B
PE:-11.23
High:40.36
Open:40.22
Low:39.20
Close:40.67
Loading ...

Revolution Medicines price target raised to $87 from $82 at Guggenheim

TIPRANKS
·
03 Dec 2024

Revolution Medicines’ Promising RAS(ON) Portfolio and Strategic Growth Opportunities Justify Buy Rating

TIPRANKS
·
03 Dec 2024

Revolution Medicines Price Target Maintained With a $68.00/Share by Needham

Dow Jones
·
03 Dec 2024

U.S. RESEARCH ROUNDUP-Citigroup, Salesforce, Zscaler

Reuters
·
03 Dec 2024

Revolution Medicines Inc : JP Morgan Raises Target Price to $71 From $63

THOMSON REUTERS
·
03 Dec 2024

BRIEF-Revolution Medicines Announces Commencement Of Public Offering Of Common Stock

Reuters
·
03 Dec 2024

Revolution Medicines Launches $600 Million Offering of Common Shares

MT Newswires Live
·
03 Dec 2024

Revolution Medicines Announces Commencement of Public Offering of Common Stock

THOMSON REUTERS
·
03 Dec 2024

Revolution Medicines Announces Commencement of Public Offering of Common Stock

GlobeNewswire
·
03 Dec 2024

Sector Update: Health Care Stocks Slipping Late Afternoon

MT Newswires Live
·
03 Dec 2024

Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating

MT Newswires Live
·
03 Dec 2024

Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

MT Newswires Live
·
03 Dec 2024

Dow Dips 150 Points; ISM Manufacturing PMI Tops Estimates

Benzinga
·
03 Dec 2024

Revolution Medicines Down Over 13%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
02 Dec 2024

Revolution Medicines Provides Clinical Updates From Its Ras(on) Inhibitor Portfolio

THOMSON REUTERS
·
02 Dec 2024

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

GlobeNewswire
·
02 Dec 2024

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

GlobeNewswire
·
28 Nov 2024

JPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REG

seekingalpha
·
26 Nov 2024

Revolution Medicines (RVMD) Receives a Buy from Bank of America Securities

TIPRANKS
·
15 Nov 2024

Promising Outlook for Revolution Medicines: Buy Rating Backed by Strong RAS ON Inhibitor Progress and Financial Stability

TIPRANKS
·
11 Nov 2024